Fenofibrate plus statin and ASCVD risk by triglyceride-rich lipoprotein cholesterol in 70,000 patients. [PDF]
Jang Y +6 more
europepmc +1 more source
Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk. [PDF]
Luo J +10 more
europepmc +1 more source
Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components. [PDF]
Lee S +6 more
europepmc +1 more source
Phototherapy Alone or Combined with Adjuvant Drugs for Neonatal Hyperbilirubinemia: A Systematic Review and Network Meta-Analysis. [PDF]
Fei Q, Liu H, Wang X, Yuan T.
europepmc +1 more source
Delphi Consensus on the Use of Fenofibrate as Systemic Therapy for the Prevention of Diabetic Retinopathy Progression. [PDF]
O'Brien RC +9 more
europepmc +1 more source
Importance and Management of Non-High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment. [PDF]
O'Brien RC +11 more
europepmc +1 more source
Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia. [PDF]
Liu H +9 more
europepmc +1 more source
Fenofibrate suppresses <i>Mycoplasma bovis</i> infection via autophagy-mediated cholesterol regulation in bovine mammary epithelial cells and murine mammary tissue. [PDF]
Xu M +9 more
europepmc +1 more source
A case of lipoprotein glomerulopathy in which complete remission was achieved by pemafibrate therapy. [PDF]
Tomita C +7 more
europepmc +1 more source

